0001638599-20-000977.txt : 20201217 0001638599-20-000977.hdr.sgml : 20201217 20201217160616 ACCESSION NUMBER: 0001638599-20-000977 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201215 FILED AS OF DATE: 20201217 DATE AS OF CHANGE: 20201217 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Patel Mahesh V. CENTRAL INDEX KEY: 0001579872 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36357 FILM NUMBER: 201396173 MAIL ADDRESS: STREET 1: C/O LIPOCINE, INC. STREET 2: 675 ARAPEEN DRIVE, STE. 202 CITY: SALT LAKE CITY STATE: UT ZIP: 84108 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Lipocine Inc. CENTRAL INDEX KEY: 0001535955 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 990370688 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 BUSINESS PHONE: 801 994 7383 MAIL ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 FORMER COMPANY: FORMER CONFORMED NAME: MARATHON BAR CORP DATE OF NAME CHANGE: 20111130 4 1 doc4_6960.xml PRIMARY DOCUMENT X0306 4 2020-12-15 0 0001535955 Lipocine Inc. LPCN 0001579872 Patel Mahesh V. 675 ARAPEEN DRIVE SUITE 202 SALT LAKE CITY UT 84010 1 1 0 0 Chief Executive Officer Common Stock 2020-12-16 4 M 0 45000 0 A 1243090 D Common Stock 2020-12-16 4 S 0 15000 1.35 D 1228090 D Stock Option (Right to Buy) 1.37 2020-12-15 4 A 0 375000 1.37 A 2021-12-15 2030-12-15 Common Stock 375000 375000 D Restricted Stock Unit 0 2020-12-16 4 M 0 45000 0 A 2020-12-16 2027-01-25 Common Stock 45000 45000 D Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 15, 2021, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorata basis over the following two years. Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of TLANDO. Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. /s/Mahesh V Patel 2020-12-17